New resources and models to improve understanding and treatment of myelodysplastic syndromes
Development of Innovative Resources to Advance MDS Research
['FUNDING_OTHER'] · FRED HUTCHINSON CANCER CENTER · NIH-11142456
Researchers are creating lab tools, patient-like cell lines, drug-response maps, and immune targets to help people with myelodysplastic syndromes (MDS) get more personalized treatment options.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11142456 on ClinicalTrials.gov |
What this research studies
This project will build a roadmap of the common mutations in MDS and create induced pluripotent stem cell (iPSC)-derived blood stem cell lines that reflect patients' disease. The team will test many drugs on these molecularly defined cell lines and link the results to clinical data to show which treatments might work best for different MDS types. They will also catalogue new antigen targets and develop models to support adoptive T cell immunotherapy approaches for MDS. These shared resources are meant to help researchers design better, more targeted therapies for people with MDS.
Who could benefit from this research
Good fit: Ideal candidates are people with MDS who are willing to donate blood or bone marrow samples, share clinical information, or consider joining future trials based on these resources.
Not a fit: People without MDS or those whose disease-causing mutations are not represented in the created models may not receive direct benefit from this project.
Why it matters
Potential benefit: If successful, this could speed up development of more personalized treatments, improve selection of effective drugs, and enable targeted immunotherapies for MDS patients.
How similar studies have performed: Similar methods—using iPSC models and drug-sensitivity testing tied to patient data—have shown promise in other blood cancers, but combining these specific resources for MDS is relatively novel.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BLEAKLEY, MARIE — FRED HUTCHINSON CANCER CENTER
- Study coordinator: BLEAKLEY, MARIE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.